%0 Journal Article
%K *Cardiovascular Diseases/epidemiology/prevention & control
%K *Diabetes Mellitus, Type 2/complications/drug therapy
%K *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
%K Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
%K Glucose
%K *Heart Failure/epidemiology
%K Hospitalization
%K Humans
%K *Myocardial Infarction
%K Primary health care
%K *Renal Insufficiency, Chronic/complications/epidemiology
%K Retrospective Studies
%K Sodium
%K *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
%K *Symporters
%K United Kingdom/epidemiology
%K Cardiovascular disease
%K clinical trial
%K dapagliflozin
%K diabetes complications
%K dipeptidyl peptidase-4 inhibitor
%K heart failure
%B Diabetes Obes Metab
%D 2021
%G eng
%M 33973690
%P 2207-2214
%R 10.1111/dom.14437
%T Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease
%V 23
%2 PMC8518855
%7 2021/05/12
%@ 1462-8902 (Print)1462-8902